Latest:
Dr. Maris on Key Results From the OUTREACH Trial of Liso-cel in DLBCL
Michael Maris, MD, discusses key efficacy and safety data from the phase 2 OUTREACH trial in diffuse large B-cell lymphoma.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Gustavo Werutsky, MD, PhD
Gustavo Werutsky, MD, PhD, is a medical oncologist in the Breast Cancer Program at Hospital Moinhos de Vento and investigator at the Oncology Research Centre, Hospital São Lucas PUCRS University.
Latest:
Dr Werutsky on Assessing the Prognostic Value of HER2-Low in Early Breast Cancer
Gustavo Werutsky, MD, PhD, discusses an exploratory analysis assessing the prognostic value of HER2-low in early breast cancer management.
Geoffrey Liu, MSc, MD
Geoffrey Liu, MSc, MD, is a senior scientist at Princess Margaret Cancer Centre and a professor in the Epidemiology Division at Dalla Lana School of Public Health of the University of Toronto in Canada.
Latest:
Dr Liu on Updated Efficacy and Safety Data With Taletrectinib in ROS1+ NSCLC
Geoffrey Liu, MSc, MD, discusses updated efficacy and safety results with taletrectinib in ROS1-positive non–small cell lung cancer.
Mark H. Bilsky, MD
Latest:
Overall Survival After Surgery for Spinal Metastases Has Improved Over the Past Two Decades
Postoperative survival after surgery for spinal metastases has improved over the past 20 years, particularly in patients with kidney, breast, lung, and colon tumors metastatic to the spine.
Peter J. DeMaria, MD, and Jennifer J. Gao, MD
Latest:
Career Options for Graduating Oncology Fellows at the NIH and FDA
Peter J. DeMaria, MD and Jennifer J. Gao, MD shed light on how graduating fellows seeking a rewarding and intellectually challenging career on the frontier of cancer drug development could be well served to consider a position of federal service at the NIH or FDA.
Foluso Bisi Ademuyiwa, MD, MPH, MSCI
Latest:
Dr Ademuyiwa on the Sequencing of First-line CDK4/6 Inhibitors in HR+/HER2– Breast Cancer
Foluso Bisi Ademuyiwa, MD, MPH, MSCI, discusses the optimal sequencing of current CDK4/6 inhibitors in the first-line setting for hormone receptor (HR)–positive, HER2-negative breast cancer based on updated efficacy and safety data.
Kim Nguyen Chi, MD, FRCPC
Kim Nguyen Chi, MD, FRCPC, is a medical oncologist at Vancouver Cancer Centre and Vancouver Prostate Centre, chief medical officer and Shrum Chair in Prostate Cancer Research for BC Cancer – Vancouver, and a professor in the faculty of Health Sciences at Simon Fraser University.
Latest:
Dr Chi on Potential Prognostic Markers for Lutetium Lu 177 Vipivotide Tetraxetan in PSMA+ mCRPC
Kim Nguyen Chi, MD, FRCPC, discusses correlative analyses of prognostic subgroups in the phase 2 PR21 study in PSMA-positive mCRPC.
Kim N. Chi, MD, BC Cancer
Latest:
Rapid Readouts: Final Analysis Results From the Phase 3 TITAN Study
Kim N. Chi, MD, presents slides from the 2021 ASCO Genitourinary Cancers Symposium for the final results from the phase 3 TITAN study of apalutamide versus placebo in patients with metastatic castration-sensitive prostate cancer receiving androgen deprivation therapy.
Adriana Rossi, MD
Latest:
EHA 2025 Insights: Emerging Developments and Future Perspectives for the Multiple Myeloma Treatment Landscape
Panelists discuss how emerging combination therapies such as bispecific antibodies with chimeric antigen receptor (CAR) T cells show promising response rates in patients with heavily refractory disease, while highlighting the ongoing unmet need to improve treatment access and educate community practices on advanced therapies.